Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: March 4, 2009

Drug Name Review Type Class Manufacturer
Sancuso New Drug Initial Review Antiemetic ProStrakan
Moxatag New Drug Initial Review Antibiotic MiddleBrook
Astepro New Drug Initial Review Nasal Preprarations Meda
Trilipix New Drug Initial Review Lipotropics � Other Abbott
Stavzor New Drug Initial Review Anticonvulsant Noven
Janumet New Drug Initial Review Diabetes Merck
Banzel New Drug Initial Review Anticonvulsant Eisai
Tekturna HCT New Drug Initial Review Direct Renin Inhibitor Novartis
Letairis New Drug Appeal Pulmonary Arterial Hypertension Gilead
Megace ES New Drug Appeal Progestin Par
Bystolic New Drug Appeal Beta-Blocker Forest
Pristiq New Drug Appeal SNRI Antidepressant Wyeth
Keppra XR New Drug Appeal Anticonvulsant UCB
Exforge New Drug Appeal Antihypertensive Combination Novartis
Tekturna New Drug Appeal Direct Renin Inhibitor Novartis